f Oral TLR8 Agonist Selgantolimod on HBsAg in Participants with Both Chronic Hepatitis B and HIV

The purpose of this study is to see how safe and tolerable SLGN is, and how well it reduces the amount of hepatitis B virus in people with CHB and HIV. Results from this study could help evaluate whether SLGN can lower the amount of hepatitis B virus in blood and prevent illness in people with CHB and HIV, without the need for life-long therapy. SLGN has not been tested in people with HIV